Shares of Hologic, Inc. (NASDAQ:HOLX) have earned an average rating of “Buy” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $47.77.

Several brokerages have recently weighed in on HOLX. Bank of America Corporation reaffirmed a “neutral” rating and set a $48.00 price target (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price target on shares of Hologic in a report on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a report on Friday, July 14th. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Barclays PLC reissued an “overweight” rating and set a $53.00 target price (up previously from $50.00) on shares of Hologic in a report on Monday, July 17th.

COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Receives Consensus Recommendation of “Buy” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/02/hologic-inc-holx-receives-consensus-recommendation-of-buy-from-brokerages.html.

In other news, Director Lawrence M. Levy sold 9,596 shares of the company’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lawrence M. Levy sold 7,138 shares of the company’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $37.38, for a total value of $266,818.44. The disclosure for this sale can be found here. Insiders sold a total of 23,873 shares of company stock valued at $898,754 in the last 90 days. Corporate insiders own 0.79% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of HOLX. Teachers Advisors LLC lifted its holdings in Hologic by 36.4% during the 1st quarter. Teachers Advisors LLC now owns 877,549 shares of the medical equipment provider’s stock worth $37,340,000 after purchasing an additional 234,002 shares in the last quarter. Janus Capital Management LLC increased its stake in Hologic by 21.5% in the 1st quarter. Janus Capital Management LLC now owns 422,423 shares of the medical equipment provider’s stock worth $17,974,000 after acquiring an additional 74,650 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its stake in Hologic by 8.2% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 35,498 shares of the medical equipment provider’s stock worth $1,510,000 after acquiring an additional 2,700 shares during the last quarter. DnB Asset Management AS increased its stake in Hologic by 42.6% in the 2nd quarter. DnB Asset Management AS now owns 27,805 shares of the medical equipment provider’s stock worth $1,262,000 after acquiring an additional 8,300 shares during the last quarter. Finally, Xact Kapitalforvaltning AB increased its stake in Hologic by 9.9% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 63,419 shares of the medical equipment provider’s stock worth $2,878,000 after acquiring an additional 5,735 shares during the last quarter. 95.68% of the stock is currently owned by institutional investors and hedge funds.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the prior year, the business posted $0.51 EPS. Hologic’s revenue was up 12.4% on a year-over-year basis.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.